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The risk of Alzheimer's disease (AD) is higher in patients with type 2 diabetes mellitus (T2DM). Previous
studies in high-fat diet-induced AD animal models have shown that brain insulin resistance in these
animals leads to the accumulation of amyloid beta (Ab) and the reduction in GSK-3b phosphorylation,
which promotes tau phosphorylation to cause AD. No therapeutic treatments that target AD in T2DM
patients have yet been discovered. Agmatine, a primary amine derived from L-arginine, has exhibited
anti-diabetic effects in diabetic animals. The aim of this study was to investigate the ability of agmatine
to treat AD induced by brain insulin resistance. ICR mice were fed a 60% high-fat diet for 12 weeks and
received one injection of streptozotocin (100 mg/kg/ip) 4 weeks into the diet. After the 12-week diet, the
mice were treated with agmatine (100 mg/kg/ip) for 2 weeks. Behaviour tests were conducted prior to
sacriﬁce. Brain expression levels of the insulin signal molecules p-IRS-1, p-Akt, and p-GSK-3b and the
accumulation of Ab and p-tau were evaluated. Agmatine administration rescued the reduction in insulin
signalling, which in turn reduced the accumulation of Ab and p-tau in the brain. Furthermore, agmatine
treatment also reduced cognitive decline. Agmatine attenuated the occurrence of AD in T2DM mice via
the activation of the blunted insulin signal.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical and epidemiological studies indicate a higher risk of
Alzheimer's disease (AD) among patients with type 2 diabetes
mellitus (T2DM) (Craft and Watson, 2004). Previous studies have
found a high-fat diet to be common risk factor for T2DM and AD
(Edwards et al., 2011; Valls-Pedret and Ros, 2013; Willette et al.,
2015). Based on this work, rodents models with various diet-
induced AD-like alterations have been established to examine the
pathogenesis of AD in T2DM (Arnold et al., 2014; Luo et al., 1998;
McNeilly et al., 2011; Stranahan et al., 2008). Using these models,
several studies have demonstrated that brain insulin resistance isYonsei University College of
Ltd. This is an open access article ulikely to be the main cause of AD-like alterations (Haan, 2006;
Jayaraman and Pike, 2014; Kim and Feldman, 2012; Ma et al.,
2015). Insulin signalling is important for various neuronal func-
tions (Belﬁore et al., 2009), andmay be involved in the regulation of
synaptic activities, cognitive processes (Zhao and Alkon, 2001), and
learning and memory (Kim and Feldman, 2015). Furthermore, in-
sulin stimulates Ab extracellular secretion to inhibit its intracellular
accumulation (de la Monte, 2012; Gasparini et al., 2001; Pratico
et al., 2001; Watson et al., 2003) and blocks GSK-3b via phos-
phorylation to inhibit neuronal tau phosphorylation (Balaraman
et al., 2006; Clodfelder-Miller et al., 2005; Schubert et al., 2004;
Takashima, 2006). Therefore, AD may develop when insulin is un-
able to work in the brain due to brain insulin resistance (Kim and
Feldman, 2012).
An adequate therapeutic treatment that targets AD in T2DM
patients has not yet been established. Although metformin, whichnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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remain controversial (Gupta et al., 2011; McNeilly et al., 2012;
Moore et al., 2013; Picone et al., 2015). Meanwhile, we believe
that agmatine could be a therapeutic option for treating AD in in-
dividuals with T2DM. Altered arginine metabolism is associated
with diabetes (Lee et al., 2011) as well as the deterioration of
memory functions, similar to those found in AD patients (Liu et al.,
2014). Arginine is metabolized into several bioactive molecules,
including agmatine. Agmatine, an endogenous aminoguanidine
compound made from arginine by arginine decarboxylase, has had
positive effects in animal models of several diseases, such as dia-
betes, stroke, spinal cord injury, and cognitive decline (Ahn et al.,
2014; Cui et al., 2012; Park et al., 2013; Song et al., 2014; Su et al.,
2009). For example, agmatine has exhibited anti-diabetic effects
in type 1 and type 2 diabetic animals (Chang et al., 2010; Hwang
et al., 2005; Ko et al., 2008; Su et al., 2009). Several studies have
demonstrated the pharmacological potential of agmatine in treat-
ing cognitive decline and memory impairment in various animal
models (Arteni et al., 2002; Liu and Bergin, 2009; McKay et al.,
2002; Moosavi et al., 2014; Rastegar et al., 2011; Zarifkar et al.,
2010). Recently, agmatine has been shown to improve memory
function in type 1 diabetes-induced memory decline (Bhutada
et al., 2012). Also, our previous report revealed that agmatine ac-
tivates insulin signal transductions in the brain to prevent cognitive
decline induced by an intracerebroventricular streptozotocin in-
jection (Song et al., 2014).
Although the effects of agmatine on diabetes and memory
impairment have been independently reported, the possible ther-
apeutic effect of agmatine on AD-like alterations in T2DM mice
characterized by brain insulin resistance has not yet been investi-
gated. The aim of the present study was to show that the regulation
of insulin signalling by agmatine attenuates AD-like alterations in
T2DM mice characterized by brain insulin resistance.Table 1
Diet composition.
Normal diet High fat diet
Protein (kcal %) 24.5 20
Carbohydrate (kcal %) 62.4 20
Fat (kcal %) 13.1 602. Materials and methods
2.1. Materials
Agmatine, streptozotocin, and glucose were purchased from
Sigma Aldrich (St. Louis, MO, USA). Antibodies against IRS-1, p-IRS-
1 (Tyr 632), p-tau (Ser 202, Tyr 205), TNF-a, and IL-1b were pur-
chased from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-
bodies for detecting Akt, amyloid beta, and horseradish peroxidase
(HRP)-conjugated anti-mouse, anti-rabbit, and anti-goat IgG an-
tibodies were purchased from Abcam (Cambridge, UK). Beta-actin,
FITC, or rhodamine-conjugated donkey anti-rabbit or anti-mouse
antibodies and 40,6-diamidino-2-phenylindole (DAPI) were pur-
chased from Millipore (Billerica, MA, USA). Other antibodies
against p-Akt (Ser473), p-GSK-3b (Ser9), and GSK-3b were pur-
chased from Cell Signalling Technology (Beverly, MA, USA). The
polyvinylidene diﬂuoride (PVDF) membrane for western blot assay
was purchased from Millipore. The chemiluminescence reagents
(ECL) for western blot assay were from Life Technologies (Carlsbad,
CA, USA). The high-fat diet (60% kcal fat) was purchased from
Research Diets (New Brunswick, NJ, USA) and normal diet was
purchased from LabDiet (St. Louis, MO, USA). The portable gluc-
ometer (CareSensII Meter) was purchased from Pharmaco (NZ)
Ltd. (Auckland, New Zealand). The serum insulin ELISA was pur-
chased from ALPCO (Windham, NH, USA) and tissue insulin ELISA
was purchased from Shibayagi (Gumma, Japan). The amyloid beta
ELISA is purchased from Invitrogen (Carlsbad, CA, USA). All the
other chemicals used in this experiment were purchased from
Sigma Aldrich.2.2. Establishment of the T2DM mice with AD-like alterations
characterized by brain insulin resistance
Adultmale ICRmice (7 weeks old, Central Lab Animal Inc., Seoul,
Korea) were used in this study. The mice were raised in a standard
laboratory animal facility under a 12 h light/dark cycle and had free
access to food and water ad libitum. All procedures were conducted
in accordance with the Yonsei University College of Medicine Ani-
mal Care and Use Committee and the National Institutes of Health
guidelines for the Care and Use of Laboratory Animals. Wemodiﬁed
previously established methods (Byrne et al., 2015; Jiang et al.,
2012; Luo et al., 1998; Rahigude et al., 2012; Tahara et al., 2011)to
develop a T2DM mouse model with AD-like alterations character-
ized by brain insulin resistance. After a week of acclimatization to
the laboratory conditions, mice were randomly divided into two
groups. Mice were administered either a normal chow diet (NC;
13.1% kcal fat) or a high-fat diet (HFD; 60% kcal fat) for 12 weeks
(Table 1). Themice fed HFDwere injected once at week 4with a low
dose of streptozotocin [STZ; 100 mg/kg/ip, dissolved in citrate
buffer (pH 4.4)] to shorten the time taken for the animal model to
be established by inducing partial insulin deﬁciency (Fig. 1).
Mice with fasting serum glucose level >200 mg/dl, body weight
>55 g, and impaired glucose, insulin tolerance were classiﬁed as
T2DM (Tabak et al., 2012). T2DM mice were divided into two
groups: HFD mice treated with saline and HFD mice treated with
agmatine (HFD þ AGM; 100 mg/kg/ip, dissolved in saline). These
groups were treated with agmatine daily for 2 weeks (Fig. 1).
Twelve mice were included in each group (a total of 36 mice were
used).
2.3. Determination of body weight and serum glucose levels
Body weights (BW) and fasting serum glucose levels (Piletz
et al., 2013) of all animals were monitored weekly. To measure
fasting glucose levels, micewere fasted for 4 h before the test. Blood
glucose concentrations from blood samples taken from the tip of
the tail were measured using a glucometer.
2.4. Intraperitoneal glucose tolerance test (IPGTT)
Glucose tolerance test is a widely used clinical test to diagnose
glucose intolerance and T2DM (American Diabetes, 2007;
Muniyappa et al., 2008). Food was removed a night before the
test. The mice were injected with glucose (2 g/kg/ip, dissolved in
saline). Blood glucose levels from blood samples taken from the tip
of the tail were measured using a glucometer at 0, 30, 60, and
120 min after the bolus. The area under the concentration versus
time curve (AUC glucose 0e120 min, mg/dl * minutes) was
calculated.
2.5. Intraperitoneal insulin tolerance test (IPITT)
Mice were fasted for 4 h before the test. The mice were injected
with insulin (0.75 U/kg/ip, dissolved in saline). Blood glucose levels
from blood samples taken from the tip of the tail were measured
using a glucometer at 0, 15, 30, 60, and 120 min after the bolus. The
Fig. 1. Timeline for the in vivo study. Mice were randomly assigned into two groups and then fed either a normal diet (NC) or a high-fat diet (HFD) for 12 weeks. HFD-fed mice
were injected once at week 4 with streptozotocin (STZ; 100 mg/kg/ip). Mice with a fasting serum glucose level >200 mg/dl, body weight >55 g, and impaired glucose tolerance were
selected and then randomly divided into two groups: HFD mice treated with saline and HFD mice treated with agmatine (HFD þ AGM; 100 mg/kg/ip) for 2 weeks. Behaviour tests
were conducted prior to sacriﬁce.
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0e120 min, mg/dl * minutes) was calculated.
2.6. Behaviour tests
2.6.1. Morris water maze (MWM)
TheMorris watermaze test was conducted for evaluating spatial
learning and reference memory depending on hippocampus using
a previously established protocol (Morris et al., 1982) with some
modiﬁcations. Our test consisted of 4 days of training and a test
session on day 6. Micewere transferred from their home cage to the
behaviour room to adapt to the new environment for at least
30 min before each session. The apparatus consisted of a circular
water pool (100 cm in diameter, 35 cm in height) that was ﬁlled
with opaque water to a depth of 15.5 cm. A platform (5.5 cm in
diameter, 14.5 cm in height) was placed at a ﬁxed location. Four
different ﬁgures were attached on the wall as visual cues. Each
mouse received four trainings per day for 4 consecutive days.
During each training session, the escape latency from the water to
the platform was measured. All mice were allowed to ﬁnd the
platform for a maximum of 90 s. On day 5, a test session was
conducted in which the mice were allowed to swim freely in the
pool without the platform for 90 s. The time spent in the quadrant
where the platform was previously located was measured.
2.6.2. Nest building test
The nest building test was conducted after MWM for evaluating
hippocampal function. The mice were moved into individual cages
with a cotton pad (50  50 mm, 5 g). After 24 h, each nest was
recorded and scored on a scale of 1e5 by ﬁve researchers according
to the established criteria (Deacon, 2006). These criteria include
scores for the shape of the nest and the amount of material used.
2.7. Tissue sample preparation
After the behaviour tests, the mice were transcardially perfused
with saline and their brains were removed. Two hemispheres from
each brain were randomly selected for either western blot or
immunohistochemistry. Hemispheres for immunohistochemistry
were incubated in 4% paraformaldehyde (PFA) for 24 h at 4 C and
then transferred to a 30% sucrose solution for 1 week. These
hemispheres were embedded in medium (Tissue-Tek® O.C.T.™
Compound, Sakura Finetek USA, Inc., Torrance, CA, USA), cut into
20 mm slices on a cryostat, and stored at 20 C until immuno-
histochemistry was performed. The hemispheres for western blotassay were placed in saline and carefully dissected. The hippo-
campus and cortex regions were immediately frozen in liquid ni-
trogen and stored until western blot assay.
2.8. Immunoﬂuorescence
The sections were mounted on tissue slides and then per-
meabilized with 0.025% Triton X-100. The sections were blocked
with 10% donkey serum at room temperature for 1 h. The sections
were immunostained with primary antibodies against p-tau (Ser
202, Tyr 205, 1:200), Ab (1:200), and p-GSK-3b (Ser9, 1:200) at 4 C
overnight. After the sections were washed with PBS (0.05% with
Tween 20), FITC, or rhodamine-conjugated donkey anti-rabbit or
anti-mouse antibody (1:200) was applied for 1 h at room temper-
ature. The sections were mounted on tissue slides and then counter
stained with DAPI. The tissues were visualized under a confocal
microscope (Zeiss LSM 700, Carl Zeiss, Thornwood, NY, USA).
2.9. Western blot assay
The hippocampus and cortex were treated with lysis buffer
containing inhibitor cocktails and isolated protein from the ho-
mogenizer (Dremel, Racine, WI, USA). The protein concentration
was determined using the BCA method. A total of 50 mg of protein
was separated on 6% or 10% SDS-PAGE gels and electrotransferred
onto a PVDF membrane. After blocking the membrane with 5%
bovine serum albumin, the membranes were reacted with primary
antibodies that speciﬁcally detect IRS-1 (1:1000), p-IRS-1 (Tyr 632,
1:1000), Akt (1:1000), p-Akt (Ser473, 1:1000), p-GSK-3b (Ser9,
1:1000), GSK-3b (1:1000), p-tau (Ser 202, Tyr 205, 1:1000), Ab
(1:1000), TNF-a (1:1000), IL-1b (1:1000) and b-actin (1:2500) at
4 C overnight. After washing with TBS (0.5% with Tween 20), the
membranes were reacted with HRP-conjugated anti-mouse, anti-
rabbit, or anti-goat IgG antibodies (1:3000) at room temperature
for 1 h. After washing with TBS (0.5% with Tween 20), signals were
observed using enhanced ECL reagents. The images were captured
by the chemi-luminescent image analyzer (LAS 4000, Fujiﬁlm,
Tokyo, Japan).
2.10. Serum and tissue insulin ELISA assay
Serum insulin was measured with an insulin ELISA kit (ALPCO,
Windham, NH, USA), and tissue insulin was measured with an in-
sulin ELISA kit (Shibayagi, Gumma, Japan). We loaded 10 mL of each
of the standard, control, and experimental samples into
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(mouse monoclonal anti-insulin conjugated to biotin) into each
well and incubated for 2 h at room temperature, shaking at
800 rpm on a microplate shaker. Microplates were washed six
times with 350 mL of wash buffer. Then, we added 100 mL of sub-
strate solution (tetramethylbenzidine) to each well and incubated
the samples for 15min at room temperature, shaking at 800 rpm on
amicroplate shaker. The enzymatic reactionwas stopped by adding
100 mL of stop solution to each well, and absorbance was measured
at 450 nm using a microplate reader.
2.11. Amyloid beta ELISA assay
Tissue amyloid beta was measured with an amyloid beta ELISA
kit. Samples were prepared using 5 M guanidine HCl/50 mM Tris
HCl solution with protease inhibitor cocktail containing AEBSF.
Brieﬂy, we loaded 100 mL of each of the standard, control, and
experimental samples into appropriate wells and incubated the
specimens for 2 h at room temperature. We then washed the
microplate four times with 400 mL of wash buffer. Then, 100 mL of
detection antibody was added into each well and incubated for 1 h
at room temperature. The microplate was then washed four times
with 400 mL of wash buffer. Then, we added 100 mL of HRP anti-
rabbit antibody to each well and incubated the specimens for
30min at room temperature.We thenwashed the microplate again
four times with 400 mL of wash buffer. Then, we added 100 mL of
stabilized chromogen to each well and incubated the specimens for
30 min at room temperature. The enzymatic reaction was stopped
by adding 100 mL of stop solution to each well, and absorbance was
determined at 450 nm using a microplate reader.
2.12. Serum analysis
Serum levels of total cholesterol and triglycerideweremeasured
by chemistry analyzer, Fuji dri-chem 4000i (Fuji photo ﬁlm, Tokyo,
Japan) and Fuji dri-chem slides. Fuji dri-chem slide contains suit-
able enzymes for separating a factor that we wanted to measure
from serum. 10 mL of sample was dropped onto each slide to induce
enzymatic reaction, and then slides were read using Fuji dri-chem
4000i.
2.13. Statistical analysis
All experiments were repeated at least three times, and the data
are expressed as the mean ± standard deviation (SD). Statistical
analysis was performed by a one-way analysis of variance (ANOVA),
followed by Tukey's post hoc analysis. Statistical signiﬁcance was
deﬁned as * p  0.05 and **p  0.01 vs. NC.
3. Results
3.1. Agmatine treatment restores insulin sensitivity, reducing
peripheral glucose intolerance, insulin intolerance, and serum
triglyceride levels and increasing serum insulin levels in HFD-fed
mice
To induce brain insulin resistance, 8-week-old ICRmicewere fed
a 60% high-fat diet for 12weeks. As shown in Fig. 2, the high-fat diet
induced signiﬁcant weight gain (NC vs. HFD, average weight: week
0, 39.93± 0.86mg vs. 40.68 ± 1.83mg; week 12, 48.68± 4.22mg vs.
66.69 ± 6.8 mg, Fig. 2A) and increased fasting serum glucose levels
(NC: 155 ± 13.49 mg/dl vs. HFD: 522 ± 31.6 mg/dl at 14 weeks,
Fig. 2B). Most importantly, glucose tolerance and insulin tolerance
were signiﬁcantly impaired in the HFD group, compared with the
NC group (difference of 162 095 mg/dl*min in the AUC of the IPGTTbetween the HFD and NC mice, Fig. 2C and D; difference of
27 017.5mg/dl*min in the AUC of the IPITT between the HFD andNC
mice, Fig. 2E and F). One low-dose injection of STZ was used to
mimic pancreas failure in the pathogenesis of T2DM; STZ evoked no
signiﬁcant damage to the pancreas (Supplementary Fig. 1). Despite
normal pancreatic function, characteristics of T2DM and insulin
resistance, including increases in body weight, fasting serum
glucose level, glucose intolerance and insulin intolerance, were
induced by 12 weeks of a high-fat diet.
After 2 weeks of agmatine treatment, glucose and insulin
intolerance were signiﬁcantly recovered (p > 0.01, HFD vs.
HFD þ AGM, Fig. 3FeI). While no signiﬁcant difference in body
weight or 4-hour fasting serum glucose levels were found (Fig. 3A
and B), overnight fasting serum glucose levels were signiﬁcantly
lower (Fig. 3C).
Mouse serum insulin ELISA assay revealed that the high fat-diet
increased serum insulin concentrations, compared with NC
(Fig. 3D). Serum analysis showed that HFD mice had lower total
cholesterol and higher triglyceride than NC, although agmatine
treatment lowered triglyceride levels and increased total choles-
terol level (Fig. 3E). Based on the results of IPGTT, IPITT, overnight
fasting serum glucose level, insulin ELISA, and serum analysis, we
can conclude that agmatine treatment restores insulin sensitivity in
high-fat diet fed mice.
3.2. Agmatine treatment rescues reduced insulin signalling in the
brain of HFD-fed mice
To evaluate the effect of agmatine on brain insulin resistance
induced by the high-fat diet, the amount of insulin in the brain was
measured by ELISA, and the expression levels of p-IRS-1 and p-Akt
in both the cortex and the hippocampusweremeasured bywestern
blot assay. As seen in Fig. 4, the amount of insulin and the protein
expression levels of p-IRS-1 and p-Akt were signiﬁcantly reduced in
both the cortex and the hippocampus of the HFD mice (insulin,
p > 0.05 vs. NC; p-IRS-1, p > 0.05 vs. NC; p-Akt, p > 0.05 vs. NC),
compared with NC mice. However, HFD þ AGM mice exhibited
signiﬁcantly higher levels of insulin, p-IRS-1, and p-Akt (insulin,
p > 0.05 vs. HFD; p-IRS-1,p > 0.05 vs. HFD; p-Akt, p > 0.05 vs. HFD)
in the cortex and the hippocampus of the mice. The amount of
insulin and phosphorylated molecules in HFD þ AGM mice was
similar to those in NC mice in both the cortex (p-IRS-1, 93%, p-Akt,
166% as a percentage of NC) and the hippocampus (p-IRS-1, 94%; p-
Akt, 127% as percentage of NC).
3.3. 3Agmatine treatment restores the phosphorylation of glycogen
synthase kinase-3b in both the cortex and hippocampus of HFD-fed
mice
Among the molecules downstream from insulin, glycogen syn-
thase kinase-3b (GSK-3b) is well known to phosphorylate tau
leading to production of neuroﬁbrillary tangles and Alzheimer's
disease. Normally, insulin downstream signals inhibit GSK-3b by
phosphorylation at serine 9 so that GSK-3b cannot phosphorylate
tau. Western blot assays and immunoﬂuorescence were conducted
to conﬁrm the ability of agmatine to restore the phosphorylation of
GSK-3b in mice with brain insulin resistance. As seen in Fig. 5A and
B, the western blot assay revealed that the protein expression of p-
GSK-3b was signiﬁcantly decreased in both the cortex and the
hippocampus in HFD mice, compared with NC mice (p > 0.05 vs.
NC). However, the expression of p-GSK-3b was signiﬁcantly higher
in both the cortex and the hippocampus in HFD þ AGM mice
(p > 0.05 vs. HFD). The level of p-GSK-3b in HFD þ AGM mice was
similar to p- GSK-3b in NC mice in both the cortex (91% as a per-
centage of NC mice) and the hippocampus (95% as a percentage of
Fig. 2. High-fat diet induces changes in weight, fasting serum glucose levels, glucose tolerance test, and insulin tolerance test. (A) Changes in body weight in the high-fat diet
(HFD) group and the normal diet (NC) group for 12 weeks. (B) Changes in fasting serum glucose level in the HFD and NC groups for 12 weeks. (C) Changes in glucose level during the
intraperitoneal glucose tolerance test (IPGTT). (D) The area under the curve (AUC) of the glucose level during the IPGTT. (E) Changes in glucose level during the intraperitoneal
insulin tolerance test (IPITT). (F) The area under the curve (AUC) of the glucose level during the IPITT.*p < 0.05, **p < 0.01.
Fig. 3. Agmatine treatment ameliorates glucose intolerance, insulin intolerance, overnight fasting serum glucose, insulin level, and triglyceride, but not body weight and 4-
hours fasting serum glucose level, in high-fat diet-fed mice. Comparison in the biochemical changes between week 12 (before agmatine treatment) and week 14 (after agmatine
treatment). (A) Changes in body weight between week 12 and week 14. (B) Changes in 4-hour fasting serum glucose levels between week 12 and week 14. (C) Changes in overnight
fasting serum glucose level between week 12 and week 14. (D) Amount of insulin at week 14 as measured by ELISA. (E) Serum analysis to measure triglyceride and total cholesterol
levels at week 14. (F) Changes in glucose level during the intraperitoneal glucose tolerance test (IPGTT) at week 14. (G) Changes in the area under the curve (AUC) for glucose levels
during the IPGTT between week 12 and week 14. (H) Changes in glucose level during the intraperitoneal insulin tolerance test (IPITT) at week 14. (I) Changes in the area under the
curve (AUC) for glucose levels during the IPITT between week 12 and week 14. **p < 0.01 vs. NC, ##p < 0.01 vs. HFD þ AGM, $$ p < 0.01 in HFD þ AGM between 12 and 14 weeks.
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Fig. 4. Agmatine increases the expression levels of insulin, p-IRS-1, and p-Akt in the cortex and the hippocampus of high-fat diet-fed mice. (A) The effects of agmatine on the
protein expression levels of p-IRS-1and p-Akt in the cortex and the hippocampus as measured by western blot assay. (B) The amount of insulin in the cortex and the hippocampus of
the mice as measured by ELISA. (C) The quantiﬁcation of p-IRS-1 and p-Akt in the cortex is expressed as a percentage of the levels observed in NC mice. (D) The quantiﬁcation of p-
IRS-1 and p-Akt in the hippocampus is expressed as a percentage of the levels observed in NC mice. *p < 0.05, **p < 0.01.
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Immunoﬂuorescence revealed that the expression of p-GSK-3b
was signiﬁcantly reduced in the cortex and the hippocampus of
HFD mice, except in CA3 of the hippocampus (Fig. 5CeF) (frontal
cortex, p < 0.01 vs. NC; lateral cortex, p < 0.01 vs. NC; DG, p < 0.01
vs. NC; CA1, p < 0.01 vs. NC; CA2, p < 0.01 vs. NC). However,
repeated agmatine administration signiﬁcantly restored the
expression of p-GSK-3b in the cortex and the hippocampus (frontal
cortex, p < 0.01 vs. HFD; lateral cortex, p < 0.01 vs. HFD; CA1,
p > 0.05 vs. HFD; CA2, p < 0.01 vs. HFD; CA3, p < 0.01 vs. HFD),
except in the dentate gyrus. These results are consistent with the
western blot assay results (Fig. 5A and B).3.4. Agmatine injection attenuates the phosphorylation of tau in
both the cortex and hippocampus of high-fat diet-fed mice
Western blot assay and immunohistochemistry were conducted
to examine whether the ability of agmatine to increase the phos-
phorylation of GSK-3b leads to a reduction of phosphorylated tau in
diabetic mice with brain insulin resistance. The western blot assay
revealed that the expression of p-tau was increased in HFD mice,
compared with NC mice, in both the cortex and the hippocampus
(cortex, p < 0.01 vs. NC; hippocampus, p < 0.01 vs. NC). However,
the expression of p-tau was signiﬁcantly reduced in HFD þ AGM
mice, compared with HFD mice, in both the cortex and the hip-
pocampus (cortex, p < 0.01 vs. HFD; hippocampus, p < 0.01 vs. HFD)
(Fig. 6A and B).
Immunoﬂuorescence revealed that the number of positive p-tau
spots was signiﬁcantly increased in HFD mice, compared with NC
mice (frontal cortex, p < 0.01 vs. NC; lateral cortex, p < 0.05 vs. NC).
Repeated treatment with agmatine signiﬁcantly lowered theexpression of p-tau in the cortex (frontal cortex, p < 0.01 vs. HFD;
lateral cortex, p < 0.05 vs. HFD) (Fig. 6C and D). Similarly, the
number of positive spots of p-tau were signiﬁcantly higher in the
DG and CA3 regions of the hippocampus in HFD mice, compared
with NC mice (DG, p < 0.01 vs. NC; CA3, p<0.01 vs. NC) (Fig. 6D, F).
However, the repeated agmatine administration signiﬁcantly low-
ered the expression of p-tau in the hippocampus (DG, p < 0.01 vs.
HFD; CA1, p < 0.05 vs. HFD; CA2, p < 0.01 vs. HFD; CA3, p < 0.01 vs.
HFD) (Fig. 6E and F).3.5. Agmatine treatment reduces the accumulation of amyloid beta
in both the cortex and the hippocampus of high-fat diet-fed mice
Western blot assay, immunohistochemistry, and tissue ELISA
were conducted to investigate whether the agmatine-mediated
activation of blunted insulin signals in the brain reduces the
accumulation of Ab. As shown in Fig. 7A B, G, the western blot assay
and tissue ELISA revealed that the amount of Ab was increased in
HFD mice, compared with NC mice (hippocampus, p < 0.01 vs. NC;
cortex, p < 0.01 vs. NC). However, the expression of Ab was
signiﬁcantly decreased in HFD þ AGM mice, compared with HFD
mice (hippocampus, p < 0.01 vs. HFD; cortex, p < 0.01 vs. HFD). All
species of amyloid beta protein bands are presented in
Supplementary Fig. 2.
Immunoﬂuorescence revealed that the expression of Ab was
signiﬁcantly higher in HFD mice, compared with NC mice (frontal
cortex, p < 0.01 vs. NC; lateral cortex, p < 0.05 vs. NC). Repeated
treatment with agmatine signiﬁcantly lowered the expression of Ab
in the cortex (frontal cortex, p < 0.01 vs. HFD; lateral cortex, p< 0.05
vs. HFD) (Fig. 6C and D). The number of positive spots of Ab were
signiﬁcantly increased in the hippocampus of HFD mice, except in
Fig. 5. Agmatine increases the phosphorylation of GSK-3b in the cortex and the hippocampus of high-fat diet-fed mice. (A) The effect of agmatine on the protein expression of
p-GSK-3b in the cortex and the hippocampus as measured by western blot assay. (B) The quantiﬁcation of p-GSK-3b in the cortex and the hippocampus is expressed as a percentage
of the level observed in NC mice. (C) Fluorescence images of p-GSK-3b in the cortex. (D) The average number of positive spots of p-GSK-3b per single cell of the cortex is expressed.
(E) Fluorescence images of p-GSK-3b in the hippocampus. (F) The average number of positive spots of p-GSK-3b per single cell of the hippocampus is expressed. *p < 0.05, **p < 0.01.
The scale bars represent 20 mm. DG: dentate gyrus; CA1: CornuAmmonis 1; CA2: CornuAmmonis 2; CA3: CornuAmmonis 3.
S. Kang et al. / Neuropharmacology 113 (2017) 467e479 473the DG (CA1, p < 0.01 vs. NC; CA2, p < 0.01 vs. NC; CA3, p < 0.01 vs.
NC). Repeated agmatine administration signiﬁcantly lowered the
expression of Ab in the hippocampus, except in the DG (CA1,
p < 0.01 vs. HFD; CA2, p < 0.01 vs. HFD; CA3, p < 0.01 vs. HFD)
(Fig. 6E and F).3.6. Agmatine administration improves learning and memory
function in high-fat diet-fed mice
Behaviour tests were conducted to determine whether the
reduction in the expression levels of Ab and p-tau by agmatine
Fig. 6. Agmatine reduces the accumulation of p-tau in the cortex and the hippocampus of high-fat diet-fed mice. (A) The effect of agmatine on the protein expression of p-tau
in the cortex and the hippocampus as measured by western blot assay. (B) The quantiﬁcation of the amount of p-tau from the cortex and the hippocampus is expressed as a
percentage of the level observed in NC mice. (C) Immunoﬂuorescence images of p-tau in the cortex. (D) The average number of positive spots of p-tau per single cell in the cortex is
expressed. (E) Immunoﬂuorescence images of p-tau in the hippocampus. DG; dentate gyrus, CA1; CornuAmmonis 1, CA2; CornuAmmonis 2, CA3; CornuAmmonis 3. (F) The average
number of positive spots of p-tau per single cell in the hippocampus is expressed. *p < 0.05, **p < 0.01. The scale bars represent 20 mm.
S. Kang et al. / Neuropharmacology 113 (2017) 467e479474leads to an improvement in learning and memory function. Morris
water maze test is conducted to evaluate spatial learning and
preference memory depending on hippocampus. In addition,
MWM has been shown that there is involvement of the entorhinaland perihinal cortices, as well as involvement of the prefrontal
cortex, the cingulated cortex, the neostriatum, and perhaps even
the cerebellum in a more limited way. In the MWM, a signiﬁcant
increase in escape latency on the last day of training was observed
Fig. 7. Agmatine reduces the accumulation of amyloid beta in the cortex and the hippocampus of high-fat diet-fed mice. (A) The effect of agmatine on Ab expression in the
cortex and hippocampus as measured by western blot assay. (B) The quantiﬁcation of Ab from the cortex and the hippocampus is expressed as a percentage of the level observed in
NC mice. (C) Immunoﬂuorescence images of Ab in the cortex. (D) The average number of positive spots of Ab per single cell in the cortex is expressed. (E) Immunoﬂuorescence
images of Ab in the hippocampus. (F) The average number of positive spots of Ab per single cell in the hippocampus is expressed. (G) The amount of amyloid beta in the cortex and
the hippocampus as measured by ELISA. *p < 0.05, **p < 0.01. The scale bars represent 20 mm. DG: dentate gyrus; CA1: CornuAmmonis 1; CA2: CornuAmmonis 2; CA3: Cor-
nuAmmonis 3.
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HFD mice spent signiﬁcantly less time in the quadrant where the
platform was located during the test, compared with NC mice
(p < 0.01 vs. NC) (Fig. 8B). However, the amount of time spent in the
platform quadrant was signiﬁcantly longer in HFD þ AGM mice,
compared with HFD mice (p < 0.01 vs. HFD) (Fig. 8B).
Nest building test is conducted to evaluate hippocampal func-
tion, as some publications report that lesions of the medial preoptic
area, septum, or hippocampus impair nesting behaviour. HFD mice
received lower scores on the nest building test, compared with NC
mice (p < 0.01 vs. NC). However, HFD þ AGM mice received
signiﬁcantly higher scores than HFD mice (p < 0.01 vs. HFD)
(Fig. 8C).
Collectively, agmatine improved hippocampal functions, such as
learning and memory, induced by high-fat diet through the acti-
vation of insulin signalling in type 2 diabetic mice with AD-like
alterations characterized by brain insulin resistance (Fig. 9).Fig. 8. Agmatine improves learning, memory, and nesting function in high-fat diet fed
(MWM). *p < 0.05 vs. NC. (B) The mean time spent in the quadrant where the platform was
material used and the shape of the nest. *p < 0.05, **p < 0.01.4. Discussion
In the present study, we demonstrated the effect of agmatine on
AD-like alterations in patients with T2DM characterized by brain
insulin resistance. Agmatine administration improved insulin ac-
tions and rescued the reduced expressions of p-IRS-1, p-Akt, and p-
GSK-3b in the brain of high-fat diet-fed mice. Agmatine treatment
reduced the amounts of Ab and p-tau accumulation in the brain,
and improved impairments in learning and memory functions in
high-fat diet-fed mice.
There are two types of therapeutics of determine, insulin sen-
sitizers and drugs effective for insulin production. The latter ones
increase amounts of insulin, although agmatine did not increase
serum insulin levels (Fig. 3D). Insulin sensitizer is effective for
regulating pre-prandial serum glucose levels, not post-prandial
serum glucose levels, and agmatine showed coherent action as
shown in Fig. 3B and C. The reductions of serum insulin level, de-
creases in overnight fasting serum glucose level, and improvementmice. (A) The mean escape latency over 5 days of training on the Morris water maze
located during the test session. (C) Nest building scores were based on the amount of
Fig. 9. The effect of agmatine on brain insulin resistance. Type 2 diabetes induces
Alzheimer's disease-like alterations through blunted insulin signalling in the brain as it
leads to the accumulation of Ab, the phosphorylation of tau, and cognitive decline.
However, agmatine activates the insulin signals in the diabetic mice with AD-like al-
terations characterized by brain insulin resistance to restore normal brain function.
Agmatine reverses the Alzheimer's disease-like alterations induced by type 2 diabetes.
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group indicated that agmatine improves insulin sensitivity. Ac-
cording to some research, agmatine improves insulin sensitivity by
activation of I2-imidazolin receptors in adrenal gland in diabetic
animal models (Chang et al., 2010; Hwang et al., 2005; Ko et al.,
2008; Su et al., 2009). Accordingly, we suggest that agmatine ex-
erts anti-diabetic effects by improving insulin sensitivity. In addi-
tion that, high-fat diet lowered total cholesterol while triglyceride
level was increased by high-fat diet (Fig. 3E), suggesting triglycer-
ide takes up most cholesterol in HFD mice. However, agmatine
treated mice showed high level of total cholesterol and low level of
triglyceride, meaning most of cholesterol could be LDL, not tri-
glyceride. According to a paper, which has similar experimental
design with ours, 12 weeks of 60% high-fat diet caused increase in
triglyceride and LDL but decrease in HDL (Sharawy et al., 2016).
However, 3 weeks of agmatine treatment reduced triglyceride and
LDL. In addition to total cholesterol and triglyceride measurement,
we could say animals used in present study would show similar
changes in LDL and HDL with that reference paper.
Brain insulin resistance was induced by 12 weeks of a high-fat
diet, and was characterized by blunted insulin signal trans-
ductions as observed in the expression levels of p-IRS-1, p-Akt, and
p-GSK-3b (Figs. 4 and 5) and decreased insulin levels (Fig. 4B). Brain
insulin resistance leads to both Ab plaque formation and tau
hyperphosphorylation (Kim and Feldman, 2012). Insulin inhibits
the accumulation of Ab via the stimulation of Ab extracellular
secretion (de la Monte, 2012; Gasparini et al., 2001; Watson et al.,
2003). Insulin resistance induces oxidative stress andneuroinﬂammation, which promotes Ab accumulation and toxicity
(Pratico et al., 2001). Although GSK-3b phosphorylates tau, the
phosphorylation of GSK-3b at serine 9 by insulin inhibits its action
on tau. Therefore, a reduced insulin signal increases GSK-3b activ-
ity, leading to tau phosphorylation (Balaraman et al., 2006;
Clodfelder-Miller et al., 2005; Takashima, 2006). In our study, the
expression levels of Ab and p-tau were increased, and neuro-
inﬂammation developed in the brain of mice in the high-fat diet
group (Figs. 6 and 7, Supplementary Fig. 3), which is consistent with
previous ﬁndings.
According to prior reports, T2DM affects cognitive processes,
such as memory and executive function (Sims-Robinson et al.,
2010). The hippocampus, which has the highest concentration of
insulin receptors in the brain (Freude et al., 2009; Gammeltoft et al.,
1985), is vulnerable to insulin resistance. A high-fat diet increases
hippocampal oxidative stress, which reduces NF-E2-related factor 2
(Nrf2) signalling (Morrison et al., 2010), causes mitochondrial ho-
meostasis deﬁciency (Petrov et al., 2015), and impairs
hippocampus-dependent memory function (McNeilly et al., 2011).
The MWM test is used to evaluate spatial memory depends pri-
marily on the hippocampus. In our study, high-fat diet-fed mice
displayed spatial memory impairment (Fig. 8 A,B), which is
consistent with previous ﬁndings.
The deterioration of activities of daily living is an early sign of AD
(Filali et al., 2012;Wesson andWilson, 2011). Inmice, injuries to the
cortex and hippocampus can affect nesting behaviour (Deacon
et al., 2002, 2003). Nest building ability is negatively correlated
with Ab accumulation in the brain (Wesson and Wilson, 2011). In
our study, nest building function was impaired in HFD mice
(Fig. 9C), which suggests that brain insulin resistance induced
impairment of brain function.
The expression levels of p-IRS-1, p-Akt, and p-GSK-3b were
increased in the brain of the HFD-AGM mice up to similar levels as
those observed in NC mice. These results indicate that the insulin
signals were being transmitted and phosphorylating IRS-1, Akt, and
GSK-3b in the brain of the type 2 diabetic mice with AD-like al-
terations characterized by brain insulin resistance. Following the
activation of the blunted insulin signals in the brain, treatment with
agmatine signiﬁcantly reduced Ab and p-tau and improved mem-
ory function, which indicates that agmatine treatment reversed the
AD-like alterations in high-fat diet-fed mice.
The increased expression of p-IRS-1 in the brain by agmatine
treatment is a novel ﬁnding of this study. It has been reported that
agmatine prevents memory deﬁcits via the activation of ERK, Akt,
and GSK-3b (Moosavi et al., 2012, 2014). Our result adds to this
previous work by showing that agmatine activates not only Akt and
GSK-3b but also their upstream signal regulator IRS-1.
Among the molecules activated by insulin receptor kinase,
members of the IRS family recruit downstream signalling mole-
cules, including phosphatidylinositol 3-dinase (PI3K) (Saltiel and
Kahn, 2001). The phosphorylation of the tyrosine residues of IRS-
1 promotes the metabolic functions of insulin, whereas the
dephosphorylation of tyrosine and the phosphorylation of the
serine/threonine residues dissociate IRS-1 from the insulin receptor
and reduce insulin signalling (Kapogiannis et al., 2015). Many in-
ducers of insulin resistance activate IRS serine kinases. Among
these inducers, there are two kinds of serine kinases. One type of
serine kinase is related to insulin signalling and includes kinases,
such as the mammalian target of rapamycin (mTOR)/S6K1 and
mitogen-activated protein kinase (MAPK). The other type of serine
kinase is activated along unrelated pathways, and includes kinases,
such as GSK-3b and c-Jun NH2-terminal kinase (JNK) (Ozcan et al.,
2004). Physical exercise or pharmacological chemicals, such as
thiazolidinedione (TZD) and metformin, improve insulin action via
the inhibition of iNOS and mTOR/S6K1 signalling (Marette, 2008;
S. Kang et al. / Neuropharmacology 113 (2017) 467e479478Pilon et al., 2004). Agmatine reduces the phosphorylation of JNK
(Hong et al., 2007; Kim et al., 2015) and iNOS (Mun et al., 2010;
Wang et al., 2010) under severe conditions, such as hypoxia,
stroke, and traumatic injury. Therefore, agmatine might reduce the
phosphorylation of iNOS and JNK in the brain of the T2DM mice
with AD-like alterations characterized by brain insulin resistance to
activate IRS-1.
The rescue of the blunted insulin signal in the hippocampus and
the cortex by agmatine revived hippocampus-dependent memory
function and cortex- and hippocampus-dependent nest building
ability. HFD þ AGM mice performed better on the MWM test than
NC mice. Another reason why agmatine improves hippocampus-
dependent spatial learning is that agmatine could be able to
function as a neurotransmitter. The amount of agmatine is reduced
in the superior frontal gyrus, cerebellum, and hippocampus of AD
patients and AD rats (Liu et al., 2008a, 2014). Spatial learning en-
hances agmatine level in the hippocampus and the cortex (Leitch
et al., 2011; Liu et al., 2008b). It is, therefore, possible that agma-
tine functioned as a neurotransmitter in this study to improve
learning and memory function in the hippocampus.
Further studies are needed to conﬁrm the direct relationship
between brain insulin resistance and agmatine. Since agmatinewas
injected intraperitoneally, it is unclear whether AD-like alterations
were rescued by agmatine directly or by recovering T2DM. An
agmatine treatment in neuronal insulin resistance in vitro model
could be helpful for clarifying the direct functions of agmatine on
brain insulin resistance.
In conclusion, this study suggests that agmatine has the po-
tential to rescue AD-like alterations in T2DMmice characterized by
brain insulin resistance via the regulation of IRS-1, Akt, and GSK-3b.
Agmatine attenuates AD-like alterations caused by brain insulin
resistance by reducing Ab and p-tau, and improves impaired hip-
pocampal functions, such as learning and memory, via the activa-
tion of blunted insulin signal transduction in the brain (Fig. 9).
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